Loading…
Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs
The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cel...
Saved in:
Published in: | Leukemia research 2000, Vol.24 (1), p.1-9 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3 |
---|---|
cites | cdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3 |
container_end_page | 9 |
container_issue | 1 |
container_start_page | 1 |
container_title | Leukemia research |
container_volume | 24 |
creator | Niitsu, Nozomi Umeda, Masanori Honma, Yoshio |
description | The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β-
d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D
3 (VD
3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all-
trans retinoic acid (ATRA) or VD
3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively. |
doi_str_mv | 10.1016/S0145-2126(99)00143-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17427996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212699001435</els_id><sourcerecordid>17427996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</originalsourceid><addsrcrecordid>eNqFkM1u1TAQRi0EoreFRwB5gVBZBOzETuJVhSr-pCIWwNqa2ONiSOxiO1dkxauT9F5Rdqzs0ZzxNz6EPOHsJWe8ffWZcSGrmtftuVIv2Fo1lbxHdrzv1kvfyPtk9xc5Iac5f2eMScXVQ3LCWduItlE78vvjgmP0lkKwdIohmqVs5YjzD5w8UIPjmOk32CO13jlMGArNGLIvfu_LQku8a3goPobKBzsbH64pmCMUHbUYfy1gMcTsA655MMbr_Ig8cDBmfHw8z8jXt2--XL6vrj69-3D5-qoyoualAqkMdwNr67o3fSccDgJEi1YBWjE0fGBdD9b1qpfYdRxRyEah6dA0dddCc0aeH969SfHnjLnoyeftbxAwzlnzTtSdUu0KygNoUsw5odM3yU-QFs2Z3szrW_N606qV0rfmtVznnh4D5mFC-8_UQfUKPDsCkA2MLkEwPt9xtWBCbtjFAcPVxt5j0tl4DAatT2iKttH_Z5M_DWyjwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17427996</pqid></control><display><type>article</type><title>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Niitsu, Nozomi ; Umeda, Masanori ; Honma, Yoshio</creator><creatorcontrib>Niitsu, Nozomi ; Umeda, Masanori ; Honma, Yoshio</creatorcontrib><description>The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β-
d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D
3 (VD
3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all-
trans retinoic acid (ATRA) or VD
3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/S0145-2126(99)00143-5</identifier><identifier>PMID: 10634639</identifier><identifier>CODEN: LEREDD</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>2'-deoxycoformycin ; 9-^b-D-^Aarabinofuranosyladenine ; Acute Disease ; Adenosine Deaminase Inhibitors ; Antimetabolites, Antineoplastic - pharmacology ; Antineoplastic agents ; Ara A ; Biological and medical sciences ; Calcitriol - pharmacology ; Cell Differentiation - drug effects ; Chemotherapy ; Cladribine ; Cladribine - pharmacology ; Deoxyadenosines - pharmacology ; Differentiation ; Dose-Response Relationship, Drug ; Drug Synergism ; Enzyme Inhibitors - pharmacology ; Fludarabine ; Hematologic and hematopoietic diseases ; HL-60 Cells - drug effects ; Human myelomonocytic leukemia ; Humans ; K562 Cells - drug effects ; Leukemia, Myeloid - drug therapy ; Leukemia, Myeloid - pathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Monocytes - drug effects ; Neoplasm Proteins - antagonists & inhibitors ; Neoplastic Stem Cells - drug effects ; Pentostatin - pharmacology ; Pharmacology. Drug treatments ; Tretinoin - pharmacology ; Tumor Cells, Cultured - drug effects ; U937 Cells - drug effects ; Vidarabine - analogs & derivatives ; Vidarabine - pharmacology</subject><ispartof>Leukemia research, 2000, Vol.24 (1), p.1-9</ispartof><rights>2000 Elsevier Science Ltd</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</citedby><cites>FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1240459$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10634639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niitsu, Nozomi</creatorcontrib><creatorcontrib>Umeda, Masanori</creatorcontrib><creatorcontrib>Honma, Yoshio</creatorcontrib><title>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β-
d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D
3 (VD
3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all-
trans retinoic acid (ATRA) or VD
3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.</description><subject>2'-deoxycoformycin</subject><subject>9-^b-D-^Aarabinofuranosyladenine</subject><subject>Acute Disease</subject><subject>Adenosine Deaminase Inhibitors</subject><subject>Antimetabolites, Antineoplastic - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Ara A</subject><subject>Biological and medical sciences</subject><subject>Calcitriol - pharmacology</subject><subject>Cell Differentiation - drug effects</subject><subject>Chemotherapy</subject><subject>Cladribine</subject><subject>Cladribine - pharmacology</subject><subject>Deoxyadenosines - pharmacology</subject><subject>Differentiation</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Synergism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fludarabine</subject><subject>Hematologic and hematopoietic diseases</subject><subject>HL-60 Cells - drug effects</subject><subject>Human myelomonocytic leukemia</subject><subject>Humans</subject><subject>K562 Cells - drug effects</subject><subject>Leukemia, Myeloid - drug therapy</subject><subject>Leukemia, Myeloid - pathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Monocytes - drug effects</subject><subject>Neoplasm Proteins - antagonists & inhibitors</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Pentostatin - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Tretinoin - pharmacology</subject><subject>Tumor Cells, Cultured - drug effects</subject><subject>U937 Cells - drug effects</subject><subject>Vidarabine - analogs & derivatives</subject><subject>Vidarabine - pharmacology</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkM1u1TAQRi0EoreFRwB5gVBZBOzETuJVhSr-pCIWwNqa2ONiSOxiO1dkxauT9F5Rdqzs0ZzxNz6EPOHsJWe8ffWZcSGrmtftuVIv2Fo1lbxHdrzv1kvfyPtk9xc5Iac5f2eMScXVQ3LCWduItlE78vvjgmP0lkKwdIohmqVs5YjzD5w8UIPjmOk32CO13jlMGArNGLIvfu_LQku8a3goPobKBzsbH64pmCMUHbUYfy1gMcTsA655MMbr_Ig8cDBmfHw8z8jXt2--XL6vrj69-3D5-qoyoualAqkMdwNr67o3fSccDgJEi1YBWjE0fGBdD9b1qpfYdRxRyEah6dA0dddCc0aeH969SfHnjLnoyeftbxAwzlnzTtSdUu0KygNoUsw5odM3yU-QFs2Z3szrW_N606qV0rfmtVznnh4D5mFC-8_UQfUKPDsCkA2MLkEwPt9xtWBCbtjFAcPVxt5j0tl4DAatT2iKttH_Z5M_DWyjwA</recordid><startdate>2000</startdate><enddate>2000</enddate><creator>Niitsu, Nozomi</creator><creator>Umeda, Masanori</creator><creator>Honma, Yoshio</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>2000</creationdate><title>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</title><author>Niitsu, Nozomi ; Umeda, Masanori ; Honma, Yoshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>2'-deoxycoformycin</topic><topic>9-^b-D-^Aarabinofuranosyladenine</topic><topic>Acute Disease</topic><topic>Adenosine Deaminase Inhibitors</topic><topic>Antimetabolites, Antineoplastic - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Ara A</topic><topic>Biological and medical sciences</topic><topic>Calcitriol - pharmacology</topic><topic>Cell Differentiation - drug effects</topic><topic>Chemotherapy</topic><topic>Cladribine</topic><topic>Cladribine - pharmacology</topic><topic>Deoxyadenosines - pharmacology</topic><topic>Differentiation</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Synergism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fludarabine</topic><topic>Hematologic and hematopoietic diseases</topic><topic>HL-60 Cells - drug effects</topic><topic>Human myelomonocytic leukemia</topic><topic>Humans</topic><topic>K562 Cells - drug effects</topic><topic>Leukemia, Myeloid - drug therapy</topic><topic>Leukemia, Myeloid - pathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Monocytes - drug effects</topic><topic>Neoplasm Proteins - antagonists & inhibitors</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Pentostatin - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Tretinoin - pharmacology</topic><topic>Tumor Cells, Cultured - drug effects</topic><topic>U937 Cells - drug effects</topic><topic>Vidarabine - analogs & derivatives</topic><topic>Vidarabine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niitsu, Nozomi</creatorcontrib><creatorcontrib>Umeda, Masanori</creatorcontrib><creatorcontrib>Honma, Yoshio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niitsu, Nozomi</au><au>Umeda, Masanori</au><au>Honma, Yoshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2000</date><risdate>2000</risdate><volume>24</volume><issue>1</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><coden>LEREDD</coden><abstract>The differentiation-inducing effect of clinically applicable analogs of deoxyadenosine on myelomonocytic leukemia cells was examined. Monocytoid leukemia cells were more sensitive to the analogs than were erythroid or myeloid leukemia cells based on the inhibition of cell growth and induction of cell differentiation. Monocytoid leukemia cells were highly sensitive to combined treatment with 2′-deoxycoformycin (dCF) and 9-β-
d-arabinofuranosyladenine (Ara A) for inducing cell differentiation. Ara A induced the differentiation of monocytoid leukemia U937 and THP-1 cells at concentrations which were 1/1000–10 000 of that at which it induced the differentiation of other cell lines in the presence of dCF. In combination with a low concentration of 1α,25-dihydroxyvitamin D
3 (VD
3), the induction of the monocytic differentiation was greater in monoblastic U937 cells. Adenosine deaminase-resistant analogs such as fludarabine (FLU) and cladribine (CdA) also induced the differentiation of human myelomonocytic leukemia cells, and these analogs synergistically enhanced the differentiation induced by all-
trans retinoic acid (ATRA) or VD
3. CdA was the most potent analog for inducing the differentiation of myeloid leukemia NB4 and HL-60 cells in the presence or absence of ATRA. These findings indicate that dCF+Ara A and CdA may be effective for the therapy of acute monocytoid and myeloid leukemia, respectively.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10634639</pmid><doi>10.1016/S0145-2126(99)00143-5</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0145-2126 |
ispartof | Leukemia research, 2000, Vol.24 (1), p.1-9 |
issn | 0145-2126 1873-5835 |
language | eng |
recordid | cdi_proquest_miscellaneous_17427996 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | 2'-deoxycoformycin 9-^b-D-^Aarabinofuranosyladenine Acute Disease Adenosine Deaminase Inhibitors Antimetabolites, Antineoplastic - pharmacology Antineoplastic agents Ara A Biological and medical sciences Calcitriol - pharmacology Cell Differentiation - drug effects Chemotherapy Cladribine Cladribine - pharmacology Deoxyadenosines - pharmacology Differentiation Dose-Response Relationship, Drug Drug Synergism Enzyme Inhibitors - pharmacology Fludarabine Hematologic and hematopoietic diseases HL-60 Cells - drug effects Human myelomonocytic leukemia Humans K562 Cells - drug effects Leukemia, Myeloid - drug therapy Leukemia, Myeloid - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Monocytes - drug effects Neoplasm Proteins - antagonists & inhibitors Neoplastic Stem Cells - drug effects Pentostatin - pharmacology Pharmacology. Drug treatments Tretinoin - pharmacology Tumor Cells, Cultured - drug effects U937 Cells - drug effects Vidarabine - analogs & derivatives Vidarabine - pharmacology |
title | Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A49%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myeloid%20and%20monocytoid%20leukemia%20cells%20have%20different%20sensitivity%20to%20differentiation-inducing%20activity%20of%20deoxyadenosine%20analogs&rft.jtitle=Leukemia%20research&rft.au=Niitsu,%20Nozomi&rft.date=2000&rft.volume=24&rft.issue=1&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=0145-2126&rft.eissn=1873-5835&rft.coden=LEREDD&rft_id=info:doi/10.1016/S0145-2126(99)00143-5&rft_dat=%3Cproquest_cross%3E17427996%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c421t-a59c1fb06228c874feb4a46ed9aed4b31b078adf8985e771ee4539ec7ec3276a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17427996&rft_id=info:pmid/10634639&rfr_iscdi=true |